<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417168</url>
  </required_header>
  <id_info>
    <org_study_id>14-42</org_study_id>
    <nct_id>NCT02417168</nct_id>
  </id_info>
  <brief_title>Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study</brief_title>
  <official_title>Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CureSearch for Children's Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fevers raise the concern for serious bacterial infections in pediatric oncology patients&#xD;
      receiving chemotherapy. The gold standard for diagnosing bacteremia (bacterial infection of&#xD;
      the blood) is a blood culture. However, bacterial growth may not occur for 48 hours or there&#xD;
      can be a false negative result.&#xD;
&#xD;
      Thus, the biomarker, procalcitonin, has been investigated for its predictive ability to&#xD;
      identify bacteremia earlier than blood culture. We believe that procalcitonin can assist in&#xD;
      differentiating bacteremia from non-bacteremia infections in febrile pediatric oncology&#xD;
      patients. A reliable predictor of bacteremia infections in pediatric oncology patients should&#xD;
      decrease hospitalizations for fever and unnecessary antibiotic treatment.&#xD;
&#xD;
      In our study we will measure procalcitonin levels in pediatric oncology patients presenting&#xD;
      with fever. We will measure procalcitonin at the time of admission which is part of our&#xD;
      standard of care for febrile pediatric oncology admissions. For the purpose of our study, we&#xD;
      will additionally measure procalcitonin levels at 12 hours and at 24 hours post admission. We&#xD;
      will examine procalcitonin levels at these three timepoints to determine if elevated&#xD;
      procalcitonin levels predict bacteremia in pediatric oncology patients with and without&#xD;
      neutropenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left study site&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in procalcitonin levels</measure>
    <time_frame>24 hours</time_frame>
    <description>Procalcitonin will be measured at the time of admission (Zero hours) and at 12, at 24 hours from admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of bacteremia</measure>
    <time_frame>1 week</time_frame>
    <description>Blood will be cultured for bacteria</description>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Cancer</condition>
  <condition>Bacteremia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children between the ages of birth to seventeen years who have an existing oncologic&#xD;
        diagnosis and who present with fever to Charleston Area Medical Center Women and Children's&#xD;
        Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children between the ages of birth to seventeen years.&#xD;
&#xD;
          -  Present to Charleston Area Medical Center Women and Children's Hospital&#xD;
&#xD;
          -  Existing pediatric oncology diagnosis.&#xD;
&#xD;
          -  Temperature greater than 38.0 C or 100.5 Fahrenheit.&#xD;
&#xD;
          -  Central venous access or functional port available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any non-pediatric (eighteen years and above) oncology patient or a non-oncology&#xD;
             patient.&#xD;
&#xD;
          -  The patient does not have central venous access or a port from which the blood can be&#xD;
             drawn.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CAMC Health Systems</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

